



## Author index of volume 66

- Abe, N., see Hamaguchi, K. **66**, 163
- Advani, A., Diabetic Complications: New Diagnostic Tools and Therapeutic Advances **66**, 317
- Allen, E., see Warren, M.L. **66**, 23
- Atik, U., see Eskandari, H.G. **66**, 129
- Baik, S.H., see Choi, K.M. **66**, 57
- Bajaj, S., see Sadikot, S.M. **66**, 293
- Bajaj, S., see Sadikot, S.M. **66**, 301
- Bajaj, S., see Sadikot, S.M. **66**, 309
- Balamurugan, A.N., B. Ramakrishna, S. Gunasekaran, Insulin secretory characteristics of monkey pancreatic islets: a simple method of islet isolation and the effect of various density gradients on separation **66**, 13
- Bandyopadhyay, S., see Sadikot, S.M. **66**, 293
- Bandyopadhyay, S., see Sadikot, S.M. **66**, 301
- Bandyopadhyay, S., see Sadikot, S.M. **66**, 309
- Bashir, M.I., see Zargar, A.H. **66**, 139
- Belfiglio, M., see Franciosi, M. **66**, 277
- Bhat, M.H., see Zargar, A.H. **66**, 139
- Bogoev, M., see Rašlová, K. **66**, 193
- Bouma, J., see Keers, J.C. **66**, 157
- Bradley, C., see Riazi, A. **66**, 237
- Butler, C.L., see Dempsey, J.C. **66**, 203
- Chan, W.B., G.T.C. Ko, V.T.F. Yeung, R. Osaki, R.C.W. Ma, W.Y. So, C.C. Chow, A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients **66**, 97
- Chase, H.P., see Garg, S.K. **66**, 49
- Chen, H.-D., see Pei, D. **66**, 253
- Chen, X., H. Tian, R. Liu, Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients **66**, 41
- Cheung, N.W., Is parity associated with earlier diagnosis of type 2 diabetes? **66**, 287
- Chistiakov, D.A., K.V. Savost'yanov, M.V. Shestakova, L.A. Chuganova, M.S. Samkhalova, I.I. Dedov, V.V. Nosikov, Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23–q24 by association study in Russian type 1 diabetic patients **66**, 79
- Cho, Y.D., see Lee, G.T. **66**, 119
- Choi, D.S., see Choi, K.M. **66**, 57
- Choi, K.M., K.W. Lee, J.A. Seo, J.H. Oh, S.G. Kim, N.H. Kim, D.S. Choi, S.H. Baik, Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome **66**, 57
- Chow, C.C., **66**, 107
- Chow, C.C., see Chan, W.B. **66**, 97
- Chuganova, L.A., see Chistiakov, D.A. **66**, 79
- Cimen, M.Y.B., see Eskandari, H.G. **66**, 129
- Conway, M.J., see Warren, M.L. **66**, 23
- Dar, F.A., see Zargar, A.H. **66**, 139
- Das, S., see Sadikot, S.M. **66**, 293
- Das, S., see Sadikot, S.M. **66**, 301
- Das, S., see Sadikot, S.M. **66**, 309
- De Berardis, G., see Franciosi, M. **66**, 277
- Dedov, I.I., see Chistiakov, D.A. **66**, 79
- Dempsey, J.C., C.L. Butler, T.K. Sorensen, I.-M. Lee, M.L. Thompson, R.S. Miller, I.O. Frederick, M.A. Williams, A case-control study of maternal recreational physical activity and risk of gestational diabetes mellitus **66**, 203
- Di Nardo, B., see Franciosi, M. **66**, 277
- Dora, M., see Sadikot, S.M. **66**, 293
- Dora, M., see Sadikot, S.M. **66**, 301
- Dora, M., see Sadikot, S.M. **66**, 309
- D'Souza, A., see Garg, S.K. **66**, 49
- Egashira, T., see Tokuyama, Y. **66**, 63
- Eskandari, H.G., M.Y.B. Cimen, L. Tamer, A. Kanik, U. Atik, Short term effects of L-carnitine on serum lipids in STZ-induced diabetic rats **66**, 129
- Fang, S.C., see Pei, D. **66**, 253
- Franciosi, M., F. Pellegrini, G. De Berardis, M. Belfiglio, B. Di Nardo, S. Greenfield, S.H. Kaplan, M. Sacco, G. Tognoni, M. Valentini, A. Nicolucci, The QUED Study Group, Correlates of satisfaction for the relationship with their physician in type 2 diabetic patients **66**, 277
- Frederick, I.O., see Dempsey, J.C. **66**, 203
- Fu, C.-C., see Pei, D. **66**, 253
- Fu, H.-J., see Wang, J.-J. **66**, 183
- Funatsu, H., H. Yamashita, E. Shimizu, T. Mimura, S. Nakamura, S. Hori, Quantitative measurement of retinal thickness in patients with diabetic macular edema is useful for evaluation of therapeutic agents **66**, 219

- Gall, M.-A., see Rašlová, K. **66**, 193  
 Gans, R.O.B., see Keers, J.C. **66**, 157  
 Garg, S.K., P.A. Gottlieb, M.E. Hisatomi, A. D'Souza, A.J. Walker, K.E. Izuora, H.P. Chase, Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine **66**, 49  
 Goenka, K., see Sadikot, S.M. **66**, 293  
 Goenka, K., see Sadikot, S.M. **66**, 309  
 Gomes, M.B., V.G. Nogueira, Acute-phase proteins and microalbuminuria among patients with type 2 diabetes **66**, 31  
 Gottlieb, P.A., see Garg, S.K. **66**, 49  
 Greenfield, S., see Franciosi, M. **66**, 277  
 Guan, J.Z., see Matsui, J. **66**, 229  
 Gunasekaran, S., see Balamurugan, A.N. **66**, 13
- Haas, M.J., see Horani, M.H. **66**, 7  
 Hamaguchi, K., A. Kimura, Y. Kusuda, T. Yamashita, M. Yasunami, M. Takahasi, N. Abe, H. Yoshimatsu, Clinical and genetic characteristics of GAD antibody positive patients initially diagnosed as having type 2 diabetes **66**, 163  
 Hâncu, N., see Rašlová, K. **66**, 193  
 Haneda, M., R. Kikkawa, H. Sakai, R. Kawamori, Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy **66**, 87  
 Hatazaki, M., see Nakahara, I. **66**, 109  
 Hayashi, C., O. Ogawa, S. Kubo, N. Mitsuhashi, T. Onuma, R. Kawamori, Ankle brachial pressure index and carotid intima-media thickness as atherosclerosis markers in Japanese diabetics **66**, 269  
 Hazra, D.K., see Sadikot, S.M. **66**, 293  
 Hazra, D.K., see Sadikot, S.M. **66**, 301  
 Hazra, D.K., see Sadikot, S.M. **66**, 309  
 Hisatomi, M.E., see Garg, S.K. **66**, 49  
 Horani, M.H., M.J. Haas, A.D. Mooradian, Rapid adaptive down regulation of oxidative burst induced by high dextrose in human umbilical vein endothelial cells **66**, 7  
 Hori, M., see Nakahara, I. **66**, 109  
 Hori, S., see Funatsu, H. **66**, 219  
 Hsiao, C.-F., see Pei, D. **66**, 253  
 Hsu, W.-L., see Pei, D. **66**, 253  
 Hu, G., see Wang, J.-J. **66**, 183  
 Hung, Y.-J., see Pei, D. **66**, 253
- Ishizuka, T., see Tokuyama, Y. **66**, 63  
 Izuora, K.E., see Garg, S.K. **66**, 49
- Jain, S., see Sadikot, S.M. **66**, 293  
 Jain, S., see Sadikot, S.M. **66**, 301  
 Jain, S., see Sadikot, S.M. **66**, 309  
 Jamal, A., see Sadikot, S.M. **66**, 293  
 Jamal, A., see Sadikot, S.M. **66**, 301  
 Jamal, A., see Sadikot, S.M. **66**, 309  
 Jena, B., see Sadikot, S.M. **66**, 293  
 Jena, B., see Sadikot, S.M. **66**, 301  
 Jena, B., see Sadikot, S.M. **66**, 309
- Kajimoto, Y., see Nakahara, I. **66**, 109  
 Kanatsuka, A., see Tokuyama, Y. **66**, 63  
 Kanik, A., see Eskandari, H.G. **66**, 129  
 Kaplan, S.H., see Franciosi, M. **66**, 277  
 Kasai, N., see Matsui, J. **66**, 229  
 Kato, S., see Takayanagi, N. **66**, 245  
 Kawamori, R., see Haneda, M. **66**, 87  
 Kawamori, R., see Hayashi, C. **66**, 269  
 Kawamori, R., see Takayanagi, N. **66**, 245  
 Keers, J.C., T.P. Links, J. Bouma, R.O.B. Gans, J.C. ter Maaten, B.H.R. Wolffenduttel, W.J. Sluiter, R. Sanderman, Do diabetologists recognise self-management problems in their patients? **66**, 157  
 Kikkawa, R., see Haneda, M. **66**, 87  
 Kim, N.H., see Choi, K.M. **66**, 57  
 Kim, S.G., see Choi, K.M. **66**, 57  
 Kimura, A., see Hamaguchi, K. **66**, 163  
 Klaff, L.J., see Warren, M.L. **66**, 23  
 Ko, G.T.C., see Chan, W.B. **66**, 97  
 Komatsu, R., see Ohara, S. **66**, 133  
 Kubo, S., see Hayashi, C. **66**, 269  
 Kubota, M., see Nakahara, I. **66**, 109  
 Kuo, S.-W., see Pei, D. **66**, 253  
 Kuroda, A., see Nakahara, I. **66**, 109  
 Kusuda, Y., see Hamaguchi, K. **66**, 163
- Laway, B.A., see Zargar, A.H. **66**, 139  
 Lee, G.T., Y.D. Cho, Regulation of fibronectin levels by agmatine and spermine in mesangial cells under high-glucose conditions **66**, 119  
 Lee, I.-M., see Dempsey, J.C. **66**, 203  
 Lee, K.W., see Choi, K.M. **66**, 57  
 Leth, G., see Rašlová, K. **66**, 193  
 Li, H.-B., see Wang, J.-J. **66**, 183  
 Lian, W.-C., see Pei, D. **66**, 253  
 Links, T.P., see Keers, J.C. **66**, 157  
 Liu, R., see Chen, X. **66**, 41  
 Ludvigsson, J., see Samuelsson, U. **66**, 173  
 Lunt, H., see Wilson, M. **66**, 263
- Ma, R.C.W., see Chan, W.B. **66**, 97  
 Masoodi, S.R., see Zargar, A.H. **66**, 139  
 Matsuhashi, M., see Nakahara, I. **66**, 109  
 Matsui, J., N. Tamasawa, J. Tanabe, N. Kasai, H. Murakami, K. Yamato, J.Z. Guan, T. Suda, LDL particle size and lipid composition are risk factors for microalbuminuria in normotensive and normocholesterolemic patients with type 2 diabetes **66**, 229  
 Matsui, K., see Tokuyama, Y. **66**, 63  
 Matsuyama, T., see Ohara, S. **66**, 133  
 Metcalf, P., see Scragg, R. **66**, 147  
 Miller, R.S., see Dempsey, J.C. **66**, 203  
 Mimura, T., see Funatsu, H. **66**, 219  
 Mishra, R., see Sadikot, S.M. **66**, 293  
 Mishra, R., see Sadikot, S.M. **66**, 301  
 Mishra, R., see Sadikot, S.M. **66**, 309  
 Mitsuhashi, N., see Hayashi, C. **66**, 269  
 Mooradian, A.D., see Horani, M.H. **66**, 7

- Moore, M.P., see Wilson, M. **66**, 263  
 Mukherjee, S., see Sadikot, S.M. **66**, 293  
 Mukherjee, S., see Sadikot, S.M. **66**, 301  
 Mukherjee, S., see Sadikot, S.M. **66**, 309  
 Munichoodappa, C., see Sadikot, S.M. **66**, 293  
 Munichoodappa, C., see Sadikot, S.M. **66**, 301  
 Munichoodappa, C., see Sadikot, S.M. **66**, 309  
 Murakami, H., see Matsui, J. **66**, 229  
 Murthy, S.S., see Sadikot, S.M. **66**, 293  
 Murthy, S.S., see Sadikot, S.M. **66**, 301  
 Murthy, S.S., see Sadikot, S.M. **66**, 309
- Nabavizadeh Rafsanjani, F., J. Vahedian, The effect of insulin-dependent diabetes mellitus on basal and distention-induced acid and pepsin secretion in rat **66**, 1  
 Nakahara, I., M. Matsuhisa, Y. Shiba, A. Kuroda, Y. Nakatani, M. Hatazaki, Y. Kajimoto, M. Kubota, Y. Yamasaki, M. Hori, Acute elevation of free fatty acids impairs hepatic glucose uptake in conscious rats **66**, 109  
 Nakamura, S., see Funatsu, H. **66**, 219  
 Nakatani, Y., see Nakahara, I. **66**, 109  
 Nicolucci, A., see Franciosi, M. **66**, 277  
 Nigam, A., see Sadikot, S.M. **66**, 293  
 Nigam, A., see Sadikot, S.M. **66**, 301  
 Nigam, A., see Sadikot, S.M. **66**, 309  
 Nishiyama, K., see Takayanagi, N. **66**, 245  
 Nogueira, V.A.A.C.A.G., see Gomes, M.A.A.C.A.B. **66**, 31  
 Nomiyama, T., see Takayanagi, N. **66**, 245  
 Nosikov, V.V., see Chistiakov, D.A. **66**, 79  
 Nozaki, O., see Tokuyama, Y. **66**, 63
- Ogawa, O., see Hayashi, C. **66**, 269  
 Oh, J.H., see Choi, K.M. **66**, 57  
 Ohara, S., R. Komatsu, T. Matsuyama, Short-term effect of buformin, a biguanide, on insulin sensitivity, soluble fraction of tumor necrosis factor receptor and serum lipids in overweight patients with type 2 diabetes mellitus **66**, 133  
 Onuma, T., see Hayashi, C. **66**, 269  
 Onuma, T., see Takayanagi, N. **66**, 245  
 Osaki, R., see Chan, W.B. **66**, 97
- Padaiga, Z., see Samuelsson, U. **66**, 173  
 Patra Goenka, P., see Sadikot, S.M. **66**, 293  
 Patra, P., see Sadikot, S.M. **66**, 301  
 Patra, P., see Sadikot, S.M. **66**, 309  
 Pei, D., Y.-J. Hung, H.-D. Chen, C.-F. Hsiao, C.-C. Fu, T.-C. Yang, W.-C. Lian, S.C. Fang, W.-L. Hsu, S.-W. Kuo, The insulin sensitivity, glucose effectiveness and acute insulin response to glucose load of non-obese adolescent type 2 diabetes **66**, 253  
 Pellegrini, F., see Franciosi, M. **66**, 277  
 Pickup, J., see Riazi, A. **66**, 237  
 Prasannakumar, K.M., see Sadikot, S.M. **66**, 293  
 Prasannakumar, K.M., see Sadikot, S.M. **66**, 301  
 Prasannakumar, K.M., see Sadikot, S.M. **66**, 309  
 Ramakrishna, B., see Balamurugan, A.N. **66**, 13
- Rašlová, K., M. Bogoev, I. Raz, G. Leth, M.-A. Gall, N. Hâncu, Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes **66**, 193  
 Raz, I., see Rašlová, K. **66**, 193  
 Riazi, A., J. Pickup, C. Bradley, Daily stress and glycaemic control in Type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity **66**, 237  
 Rosenstock, J., see Warren, M.L. **66**, 23
- Sacco, M., see Franciosi, M. **66**, 277  
 Sadasivrao, Y., see Sadikot, S.M. **66**, 293  
 Sadasivrao, Y., see Sadikot, S.M. **66**, 301  
 Sadasivrao, Y., see Sadikot, S.M. **66**, 309  
 Sadauskaite, V., see Samuelsson, U. **66**, 173  
 Sadikot, S.M., A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra, K. Goenka, The burden of diabetes and impaired fasting glucose in India using the ADA 1997 criteria: prevalence of diabetes in India study (PODIS) **66**, 293  
 S.M. Sadikot, A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra Goenka, The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS) **66**, 301  
 S.M. Sadikot, A. Nigam, S. Das, S. Bajaj, A.H. Zargar, K.M. Prasannakumar, A. Sosale, C. Munichoodappa, V. Seshiah, S.K. Singh, A. Jamal, K. Sai, Y. Sadasivrao, S.S. Murthy, D.K. Hazra, S. Jain, S. Mukherjee, S. Bandyopadhyay, N.K. Sinha, R. Mishra, M. Dora, B. Jena, P. Patra, K. Goenka, Comparing the ADA 1997 and the WHO 1999 criteria: Prevalence of Diabetes in India Study **66**, 309  
 Sai, K., see Sadikot, S.M. **66**, 301  
 Sai, K., see Sadikot, S.M. **66**, 309  
 Sakai, H., see Haneda, M. **66**, 87  
 Samkhalova, M.S., see Chistiakov, D.A. **66**, 79  
 Samuelsson, U., V. Sadauskaite, Z. Padaiga, J. Ludvigsson, DEBA Study Group, A fourfold difference in the incidence of type 1 diabetes between Sweden and Lithuania but similar prevalence of autoimmunity **66**, 173  
 Sanderman, R., see Keers, J.C. **66**, 157  
 Savost'anov, K.V., see Chistiakov, D.A. **66**, 79  
 Scragg, R., P. Metcalf, Do triglycerides explain the U-shaped relation between alcohol and diabetes risk? Results from a cross-sectional survey of alcohol and plasma glucose **66**, 147  
 Seo, J.A., see Choi, K.M. **66**, 57  
 Seshiah, V., see Sadikot, S.M. **66**, 293  
 Seshiah, V., see Sadikot, S.M. **66**, 301  
 Seshiah, V., see Sadikot, S.M. **66**, 309  
 Sheikh, M.I., see Zargar, A.H. **66**, 139  
 Shestakova, M.V., see Chistiakov, D.A. **66**, 79  
 Shiba, Y., see Nakahara, I. **66**, 109  
 Shimizu, E., see Funatsu, H. **66**, 219  
 Singh, S.K., see Sadikot, S.M. **66**, 293

- Singh, S.K., see Sadikot, S.M. **66**, 301  
 Singh, S.K., see Sadikot, S.M. **66**, 309  
 Sinha, N.K., see Sadikot, S.M. **66**, 293  
 Sinha, N.K., see Sadikot, S.M. **66**, 301  
 Sinha, N.K., see Sadikot, S.M. **66**, 309  
 Sluiter, W.J., see Keers, J.C. **66**, 157  
 So, W.Y., see Chan, W.B. **66**, 97  
 Sorensen, T.K., see Dempsey, J.C. **66**, 203  
 Sosale, A., see Sadikot, S.M. **66**, 293  
 Sosale, A., see Sadikot, S.M. **66**, 301  
 Sosale, A., see Sadikot, S.M. **66**, 309  
 Suda, T., see Matsui, J. **66**, 229
- Takahasi, M., see Hamaguchi, K. **66**, 163  
 Takayanagi, N., T. Onuma, S. Kato, K. Nishiyama, T. Nomiyama, R. Kawamori, Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients **66**, 245  
 Tamasawa, N., see Matsui, J. **66**, 229  
 Tamer, L., see Eskandari, H.G. **66**, 129  
 Tan, M.Y., The relationship of health beliefs and complication prevention behaviors of Chinese individuals with Type 2 Diabetes Mellitus **66**, 71  
 Tanabe, J., see Matsui, J. **66**, 229  
 ter Maaten, J.C., see Keers, J.C. **66**, 157  
 Thompson, M.L., see Dempsey, J.C. **66**, 203  
 Tian, H., see Chen, X. **66**, 41  
 Tognoni, G., see Franciosi, M. **66**, 277  
 Tokuyama, Y., K. Matsui, T. Egashira, O. Nozaki, T. Ishizuka, A. Kanatsuka, Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population **66**, 63  
 Tuomilehto, J., see Wang, J.-J. **66**, 183  
 Vahedian, J., see Nabavizadeh Rafsanjani, F. **66**, 1
- Valentini, M., see Franciosi, M. **66**, 277  
 Walker, A.J., see Garg, S.K. **66**, 49  
 Wang, J.-J., S.-Y. Yuan, L.-X. Zhu, H.-J. Fu, H.-B. Li, G. Hu, J. Tuomilehto, Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose **66**, 183  
 Wani, A.I., see Zargar, A.H. **66**, 139  
 Warren, M.L., M.J. Conway, L.J. Klaff, J. Rosenstock, E. Allen, Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients **66**, 23  
 Williams, M.A., see Dempsey, J.C. **66**, 203  
 Wilson, M., M.P. Moore, H. Lunt, Treatment satisfaction after commencement of insulin in Type 2 diabetes **66**, 263  
 Wolffenduttel, B.H.R., see Keers, J.C. **66**, 157
- Yamasaki, Y., see Nakahara, I. **66**, 109  
 Yamashita, H., see Funatsu, H. **66**, 219  
 Yamashita, T., see Hamaguchi, K. **66**, 163  
 Yamato, K., see Matsui, J. **66**, 229  
 Yang, T.-C., see Pei, D. **66**, 253  
 Yasunami, M., see Hamaguchi, K. **66**, 163  
 Yeung, V.T.F., see Chan, W.B. **66**, 97  
 Yoshimatsu, H., see Hamaguchi, K. **66**, 163  
 Yuan, S.-Y., see Wang, J.-J. **66**, 183
- Zargar, A.H., M.I. Sheikh, M.I. Bashir, S.R. Masoodi, B.A. Laway, A.I. Wani, M.H. Bhat, F.A. Dar, Prevalence of gestational diabetes mellitus in Kashmiri women from the Indian subcontinent **66**, 139  
 Zargar, A.H., see Sadikot, S.M. **66**, 293  
 Zargar, A.H., see Sadikot, S.M. **66**, 301  
 Zargar, A.H., see Sadikot, S.M. **66**, 309  
 Zhu, L.-X., see Wang, J.-J. **66**, 183



## Subject index of volume 66

**A1C values;** Insulin glargine; Morning, evening, or split dose glargine treatment; Type 1 diabetes; Severe hypoglycemic episodes **66**, 49

**Acute insulin response after glucose load;** Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Glucose effectiveness **66**, 253

**Acute-phase proteins;** Microalbuminuria; Type 2 diabetes **66**, 31

**ADA 1997;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; WHO 1999; Prevalence; India; Urban; Rural **66**, 309

**Adolescent type 2 diabetes;** Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Glucose effectiveness; Acute insulin response after glucose load **66**, 253

**Agmatine;** Spermine; TGF- $\beta$ 1; ERK; Fibronectin **66**, 119

**Alcohol;** Diabetes; Glucose; Serum triglycerides **66**, 147

**Angiotensin II receptor blocker;** Type 2 diabetes; Proteinuria; Candesartan **66**, 87

**Angiotensin-converting enzyme inhibitor;** Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Diabetic macular edema; Vascular permeability **66**, 219

**Ankle brachial pressure index;** Carotid intima-media thickness; Cardiovascular disease; Type 2 diabetes **66**, 269

**Ankle-brachial pressure index;** Type 2 diabetes; Metabolic syndrome; Pulse wave velocity **66**, 57

**Antioxidants;** Oxidation; Hyperglycemia; Diabetes **66**, 7

**Apolipoprotein C III;** Type 2 diabetes mellitus; Sst I polymorphism; Carotid intima-media thickness **66**, 41

**Autoimmune disorders;** Type 1 diabetes; Environmental factors; Inheritance factors **66**, 173

**Biguanide;** Insulin sensitivity; Glucose clamp; TNF- $\alpha$ ; Buformin **66**, 133

**Biphasic insulin aspart;** Postprandial dosing; Type 2 diabetes **66**, 23

**Buformin;** Biguanide; Insulin sensitivity; Glucose clamp; TNF- $\alpha$  **66**, 133

**C-peptide;** Glutamic acid decarboxylase (GAD); HLA; Type 2 diabetes; Polymorphism **66**, 163

**Candesartan;** Type 2 diabetes; Proteinuria; Angiotensin II receptor blocker **66**, 87

**Cardiovascular disease;** Ankle brachial pressure index; Carotid intima-media thickness; Type 2 diabetes **66**, 269

**L-Carnitine;** Streptozotocin; Diabetes; Triglycerides; Total cholesterol **66**, 129

**Carotid intima-media thickness;** Ankle brachial pressure index; Cardiovascular disease; Type 2 diabetes **66**, 269

**Carotid intima-media thickness;** Type 2 diabetes mellitus; Apolipoprotein C III; Sst I polymorphism **66**, 41

**Chromosome 3q23–q24;** Diabetic nephropathy; Susceptibility locus; Type 1 diabetes mellitus; Russian population **66**, 79

**Complication preventive behavior;** Health beliefs; Diabetes complications; Type 2 Diabetes **66**, 71

**Daily hassles;** Type 1 diabetes; Stress; Individual differences **66**, 237

**Dense LDL;** Type 2 diabetes mellitus; Small; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245

- Diabetes complications;** Health beliefs; Complication preventive behavior; Type 2 Diabetes **66**, 71
- Diabetes mellitus;** Parity; Pregnancy **66**, 287
- Diabetes;** L-Carnitine; Streptozotocin; Triglycerides; Total cholesterol **66**, 129
- Diabetes;** Alcohol; Glucose; Serum triglycerides **66**, 147
- Diabetes;** Gastric acid; Gastric pepsin; Distension; Rat **66**, 1
- Diabetes;** Oxidation; Antioxidants; Hyperglycemia **66**, 7
- Diabetic macular edema;** Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- Diabetic nephropathy;** Chromosome 3q23–q24; Susceptibility locus; Type 1 diabetes mellitus; Russian population **66**, 79
- Diabetologists;** Distress; Medical decision-making; Referral **66**, 157
- Distension;** Diabetes; Gastric acid; Gastric pepsin; Rat **66**, 1
- Distress;** Diabetologists; Medical decision-making; Referral **66**, 157
- Endogenous glucose production;** FFA; Hepatic glucose uptake **66**, 109
- Environmental factors;** Type 1 diabetes; Autoimmune disorders; Inheritance factors **66**, 173
- ERK;** Agmatine; Spermine; TGF- $\beta$ 1; Fibronectin **66**, 119
- Evaluation of therapeutic agent;** Quantitative measurement of macular thickness; Diabetic macular edema; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- FFA;** Hepatic glucose uptake; Endogenous glucose production **66**, 109
- Fibronectin;** Agmatine; Spermine; TGF- $\beta$ 1; ERK **66**, 119
- Follow-up;** Type 2 diabetes; IFG; IGT; Predictor **66**, 183
- Frequent-sampled intravenous glucose tolerance test;** Adolescent type 2 diabetes; Insulin resistance; Glucose effectiveness; Acute insulin response after glucose load **66**, 253
- Gastric acid;** Diabetes; Gastric pepsin; Distension; Rat **66**, 1
- Gastric pepsin;** Diabetes; Gastric acid; Distension; Rat **66**, 1
- Gestational diabetes mellitus;** Glucose challenge test; Glucose tolerance test; Prevalence **66**, 139
- Gestational diabetes;** Physical activity; Pregnancy **66**, 203
- Glucagon-like peptide-1 receptor;** Glucagon-like peptide-1; Type 2 diabetes; Missense mutation; Minimal model analysis **66**, 63
- Glucagon-like peptide-1;** Glucagon-like peptide-1 receptor; Type 2 diabetes; Missense mutation; Minimal model analysis **66**, 63
- Glucose challenge test;** Gestational diabetes mellitus; Glucose tolerance test; Prevalence **66**, 139
- Glucose clamp;** Biguanide; Insulin sensitivity; TNF- $\alpha$ ; Buformin **66**, 133
- Glucose effectiveness;** Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Insulin resistance; Acute insulin response after glucose load **66**, 253
- Glucose tolerance test;** Gestational diabetes mellitus; Glucose challenge test; Prevalence **66**, 139
- Glucose;** Alcohol; Diabetes; Serum triglycerides **66**, 147
- Glutamic acid decarboxylase (GAD);** HLA; Type 2 diabetes; Polymorphism; C-peptide **66**, 163
- Gradient separation;** Monkey islet; Insulin secretion; Secretagogues; Stimulation index **66**, 13
- Health beliefs;** Diabetes complications; Complication preventive behavior; Type 2 Diabetes **66**, 71
- Hepatic glucose uptake;** FFA; Endogenous glucose production **66**, 109
- HLA;** Glutamic acid decarboxylase (GAD); Type 2 diabetes; Polymorphism; C-peptide **66**, 163

- Hyperglycemia;** Oxidation; Antioxidants; Diabetes **66**, 7
- IFG;** Type 2 diabetes; Follow-up; IGT; Predictor **66**, 183
- IGT;** Type 2 diabetes; Follow-up; IFG; Predictor **66**, 183
- Impaired fasting glucose;** Type 2 diabetes; Impaired glucose tolerance; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- Impaired fasting glucose;** Type 2 diabetes; Prevalence; Urban; Rural; India **66**, 293
- Impaired glucose tolerance (IGT);** Type 2 diabetes; Prevalence; Urban India; Rural India **66**, 301
- Impaired glucose tolerance;** Type 2 diabetes; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- India;** Type 2 diabetes; Impaired fasting glucose; Prevalence; Urban; Rural **66**, 293
- India;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; Urban; Rural **66**, 309
- Individual differences;** Type 1 diabetes; Stress; Daily hassles **66**, 237
- Inheritance factors;** Type 1 diabetes; Autoimmune disorders; Environmental factors **66**, 173
- Insulin aspart;** Type 2 diabetes; Insulin detemir; Weight; Variation in FPG **66**, 193
- Insulin detemir;** Type 2 diabetes; Insulin aspart; Weight; Variation in FPG **66**, 193
- Insulin glargine;** Morning, evening, or split dose glargine treatment; Type 1 diabetes; Severe hypoglycemic episodes; A1C values **66**, 49
- Insulin resistance;** Adolescent type 2 diabetes; Frequent-sampled intravenous glucose tolerance test; Glucose effectiveness; Acute insulin response after glucose load **66**, 253
- Insulin secretion;** Monkey islet; Gradient separation; Secretagogues; Stimulation index **66**, 13
- Insulin sensitivity;** Biguanide; Glucose clamp; TNF- $\alpha$ ; Buformin **66**, 133
- Insulin treatment;** Type 2 diabetes; Treatment satisfaction; Well-being **66**, 263
- Medical decision-making;** Diabetologists; Distress; Referral **66**, 157
- Metabolic syndrome;** Type 2 diabetes; Pulse wave velocity; Ankle-brachial pressure index **66**, 57
- Microalbuminuria;** Acute-phase proteins; Type 2 diabetes **66**, 31
- Microalbuminuria;** Small dense LDL;  $\alpha$ -Tocopherol; Oxidation; Type 2 diabetes mellitus **66**, 229
- Minimal model analysis;** Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Type 2 diabetes; Missense mutation **66**, 63
- Missense mutation;** Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Type 2 diabetes; Minimal model analysis **66**, 63
- Monkey islet;** Insulin secretion; Gradient separation; Secretagogues; Stimulation index **66**, 13
- Morning, evening, or split dose glargine treatment;** Insulin glargine; Type 1 diabetes; Severe hypoglycemic episodes; A1C values **66**, 49
- Oxidation;** Antioxidants; Hyperglycemia; Diabetes **66**, 7
- Oxidation;** Small dense LDL; Microalbuminuria;  $\alpha$ -Tocopherol; Type 2 diabetes mellitus **66**, 229
- Parity;** Diabetes mellitus; Pregnancy **66**, 287
- Patient satisfaction;** Type 2 diabetes; Quality of life; Patient–doctor relationship; Questionnaire **66**, 277
- Patient–doctor relationship;** Type 2 diabetes; Patient satisfaction; Quality of life; Questionnaire **66**, 277
- Physical activity;** Gestational diabetes; Pregnancy **66**, 203
- Polymorphism;** Glutamic acid decarboxylase (GAD); HLA; Type 2 diabetes; C-peptide **66**, 163
- Postprandial dosing;** Biphasic insulin aspart; Type 2 diabetes **66**, 23

- Postprandial lipoprotein metabolism;** Type 2 diabetes mellitus; Small; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP) **66**, 245
- Predictor;** Type 2 diabetes; Follow-up; IFG; IGT **66**, 183
- Pregnancy;** Diabetes mellitus; Parity **66**, 287
- Pregnancy;** Gestational diabetes; Physical activity **66**, 203
- Prevalence;** Gestational diabetes mellitus; Glucose challenge test; Glucose tolerance test **66**, 139
- Prevalence;** Type 2 diabetes; Impaired fasting glucose; Urban; Rural; India **66**, 293
- Prevalence;** Type 2 diabetes; Impaired glucose tolerance (IGT); Urban India; Rural India **66**, 301
- Prevalence;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; India; Urban; Rural **66**, 309
- Proteinuria;** Type 2 diabetes; Candesartan; Angiotensin II receptor blocker **66**, 87
- Pulse wave velocity;** Type 2 diabetes; Metabolic syndrome; Ankle-brachial pressure index **66**, 57
- Quality of life;** Type 2 diabetes; Patient satisfaction; Patient–doctor relationship; Questionnaire **66**, 277
- Quantitative measurement of macular thickness;** Evaluation of therapeutic agent; Diabetic macular edema; Angiotensin-converting enzyme inhibitor; Vascular permeability **66**, 219
- Questionnaire;** Type 2 diabetes; Patient satisfaction; Quality of life; Patient–doctor relationship **66**, 277
- Rat;** Diabetes; Gastric acid; Gastric pepsin; Distension **66**, 1
- Referral;** Diabetologists; Distress; Medical decision-making **66**, 157
- Remnant lipoproteins;** Type 2 diabetes mellitus; Small; Dense LDL; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Remnant-like particles (RLP);** Type 2 diabetes mellitus; Small; Dense LDL; Remnant lipoproteins; Postprandial lipoprotein metabolism **66**, 245
- Rural India;** Type 2 diabetes; Impaired glucose tolerance (IGT); Prevalence; Urban India **66**, 301
- Rural;** Type 2 diabetes; Impaired fasting glucose; Prevalence; Urban; India **66**, 293
- Rural;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban **66**, 309
- Russian population;** Chromosome 3q23–q24; Diabetic nephropathy; Susceptibility locus; Type 1 diabetes mellitus **66**, 79
- Secretagogues;** Monkey islet; Insulin secretion; Gradient separation; Stimulation index **66**, 13
- Serum triglycerides;** Alcohol; Diabetes; Glucose **66**, 147
- Severe hypoglycemic episodes;** Insulin glargine; Morning, evening, or split dose glargin treatment; Type 1 diabetes; A1C values **66**, 49
- Small dense LDL;** Microalbuminuria;  $\alpha$ -Tocopherol; Oxidation; Type 2 diabetes mellitus **66**, 229
- Small;** Type 2 diabetes mellitus; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Spermine;** Agmatine; TGF- $\beta$ 1; ERK; Fibronectin **66**, 119
- Sst I polymorphism;** Type 2 diabetes mellitus; Apolipoprotein C III; Carotid intima-media thickness **66**, 41
- Stimulation index;** Monkey islet; Insulin secretion; Gradient separation; Secretagogues **66**, 13
- Streptozotocin;** L-Carnitine; Diabetes; Triglycerides; Total cholesterol **66**, 129
- Stress;** Type 1 diabetes; Daily hassles; Individual differences **66**, 237
- Susceptibility locus;** Chromosome 3q23–q24; Diabetic nephropathy; Type 1 diabetes mellitus; Russian population **66**, 79
- TGF- $\beta$ 1;** Agmatine; Spermine; ERK; Fibronectin **66**, 119
- TNF- $\alpha$ ;** Biguanide; Insulin sensitivity; Glucose clamp; Buformin **66**, 133
- $\alpha$ -Tocopherol;** Small dense LDL; Microalbuminuria; Oxidation; Type 2 diabetes mellitus **66**, 229

- Total cholesterol;** L-Carnitine; Streptozotocin; Diabetes; Triglycerides **66**, 129
- Treatment satisfaction;** Type 2 diabetes; Insulin treatment; Well-being **66**, 263
- Triglycerides;** L-Carnitine; Streptozotocin; Diabetes; Total cholesterol **66**, 129
- Type 1 diabetes mellitus;** Chromosome 3q23–q24; Diabetic nephropathy; Susceptibility locus; Russian population **66**, 79
- Type 1 diabetes;** Autoimmune disorders; Environmental factors; Inheritance factors **66**, 173
- Type 1 diabetes;** Insulin glargine; Morning, evening, or split dose glargine treatment; Severe hypoglycemic episodes; A1C values **66**, 49
- Type 1 diabetes;** Stress; Daily hassles; Individual differences **66**, 237
- Type 2 diabetes mellitus;** Apolipoprotein C III; Sst I polymorphism; Carotid intima-media thickness **66**, 41
- Type 2 diabetes mellitus;** Small dense LDL; Microalbuminuria;  $\alpha$ -Tocopherol; Oxidation **66**, 229
- Type 2 diabetes mellitus;** Small; Dense LDL; Remnant lipoproteins; Remnant-like particles (RLP); Postprandial lipoprotein metabolism **66**, 245
- Type 2 diabetes;** Acute-phase proteins; Microalbuminuria **66**, 31
- Type 2 diabetes;** Ankle brachial pressure index; Carotid intima-media thickness; Cardiovascular disease **66**, 269
- Type 2 diabetes;** Biphasic insulin aspart; Postprandial dosing **66**, 23
- Type 2 diabetes;** Follow-up; IFG; IGT; Predictor **66**, 183
- Type 2 diabetes;** Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Missense mutation; Minimal model analysis **66**, 63
- Type 2 diabetes;** Glutamic acid decarboxylase (GAD); HLA; Polymorphism; C-peptide **66**, 163
- Type 2 Diabetes;** Health beliefs; Diabetes complications; Complication preventive behavior **66**, 71
- Type 2 diabetes;** Impaired fasting glucose; Prevalence; Urban; Rural; India **66**, 293
- Type 2 diabetes;** Impaired glucose tolerance (IGT); Prevalence; Urban India; Rural India **66**, 301
- Type 2 diabetes;** Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Urban; Rural **66**, 309
- Type 2 diabetes;** Insulin detemir; Insulin aspart; Weight; Variation in FPG **66**, 193
- Type 2 diabetes;** Insulin treatment; Treatment satisfaction; Well-being **66**, 263
- Type 2 diabetes;** Metabolic syndrome; Pulse wave velocity; Ankle-brachial pressure index **66**, 57
- Type 2 diabetes;** Patient satisfaction; Quality of life; Patient–doctor relationship; Questionnaire **66**, 277
- Type 2 diabetes;** Proteinuria; Candesartan; Angiotensin II receptor blocker **66**, 87
- Urban India;** Type 2 diabetes; Impaired glucose tolerance (IGT); Prevalence; Rural India **66**, 301
- Urban;** Type 2 diabetes; Impaired fasting glucose; Prevalence; Rural; India **66**, 293
- Urban;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; WHO 1999; Prevalence; India; Rural **66**, 309
- Variation in FPG;** Type 2 diabetes; Insulin detemir; Insulin aspart; Weight **66**, 193
- Vascular permeability;** Quantitative measurement of macular thickness; Evaluation of therapeutic agent; Diabetic macular edema; Angiotensin-converting enzyme inhibitor **66**, 219
- Weight;** Type 2 diabetes; Insulin detemir; Insulin aspart; Variation in FPG **66**, 193
- Well-being;** Type 2 diabetes; Insulin treatment; Treatment satisfaction **66**, 263
- WHO 1999;** Type 2 diabetes; Impaired glucose tolerance; Impaired fasting glucose; ADA 1997; Prevalence; India; Urban; Rural **66**, 309

